Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 20, 2024 -- Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, according to a study published online Sept. 18 in the New England Journal of Medicine to coincide with the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
Andrea B. Apolo, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues conducted a phase 3 trial involving patients with high-risk muscle-invasive urothelial carcinoma. Participants were randomly assigned to receive pembrolizumab (200 mg) every three weeks for one year or to undergo observation after radical surgery (354 and 348 patients, respectively). In the intention-to-treat population, the coprimary end points were disease-free and overall survival.
Patients were followed for a median of 44.8 months for disease-free survival as of July 5, 2024. The researchers found that median disease-free survival was 29.6 and 14.2 months with pembrolizumab and observation, respectively (hazard ratio for disease progression or death, 0.73). Regardless of attribution, grade 3 or higher adverse events occurred in 50.7 and 31.6 percent of patients in the pembrolizumab and observation groups, respectively.
"Taking the data in total, adjuvant checkpoint inhibitor therapy lengthens disease-free survival in certain patients with high-risk muscle-invasive urothelial cancer," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
FRIDAY, Sept. 6, 2024 -- Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell...
Ruling Out Other Conditions Needed With Suspected Interstitial Cystitis
WEDNESDAY, Sept. 4, 2024 -- Efforts to rule out bladder tumors and tuberculosis are still essential in the follow-up of patients with suspected interstitial cystitis (IC)...
NECTIN4 Amplifications Predict Outcomes in Metastatic Urothelial Cancer
WEDNESDAY, May 8, 2024 -- For patients with metastatic urothelial cancer (mUC), NECTIN4 amplifications predict anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.